[Antitumor research on human laryngeal carcinoma with combined application of VP3 gene, IL-18 gene and HN gene].

Objective: To research the antitumor efficacy on mice model bearing H22 tumor with application of pVVP3IL-18HN and its mechanism of the antitumor effect on Hep-2.
Method: pVVP3IL-18HN was introduced into Hep-2 cells by liposome, then cellular morphology was observed through AO/EB stain. To evaluate the mechanism of the antitumor effect on Hep-2 of pVVP3IL-18HN and its effect on tumor immunogenicity, flow cytometer (FCM) was used to detect the variation of mitochondrial trans-membrane potential,reactive oxygen species (ROS) and the MHC-I. C57BL/6 mice were subcutaneously inoculated with 2 X 10(5) H22 tumor cells in the right hindlimb, and 7, 14 and 21 day post-inoculation, pVVP3IL-18HN was administrated intratumorally. The pVVP3, pVIL-18, PVHN and PBS control group were treated as above. Then the tumor suppression and specific cytotoxic T lymphocyte (CTL) activity was detected.
Result: After the transfection of pVVP3IL-18HN, tumor cells crenated and stained by AO/EB. In the research pVVP3IL-18HN was found to up-regulate the value of ROS and the expression of MHC-I, and down-regulate the value of mitochondrial trans-membrane potential. The tumor suppression rate of pVVP3IL-18HN was 60.5% and a dramatically increased tumor suppression was revealed in the pVVP3IL-18HN treated mice as compared with control mice treated with PBS (P < 0.05).
Conclusion: pVVP3IL-18HN kill the tumor cells by apoptosis and have notable antitumor effect in vivo.